


Illustrative Bridge from 2025 Pro Forma Adjusted EBITDA from Continuing Operations to 2026 Adjusted EBITDA Guidance

\$ millions



Represents \$100M run-rate synergies

¹ 2025 Unaudited financial results presented reflect the continuing operations of Keenova Therapeutics plc.
² Represents synergies realized, substantially all of which occurred following the separation, a portion of which was conveyed to Par Health.
³ On a pro forma basis, assuming separation took place at the beginning of each period presented, represents certain corporate costs that were conveyed to Par Health from the beginning of the period to the date of the separation.
⁴ Represents transaction-related compensation expenses (primarily related to expenses under the Transaction Incentive Plan).